... (SVEA) is a marker of foci that may initiate atrial fibrillation (AF) and is associated with worse survival. The types and frequencies of SVEA for predicting postoperative AF (POAF), new-onset AF, and clinical outcomes in obstructive hypertrophic cardiomyopathy (oHCM) remain unknown. Methods...

... This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Abstract Background Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder and a leading cause...

.... Further research is needed to elucidate the pathogenesis and develop safer and cheaper approaches to diagnose MYH7-induced restrictive cardiomyopathy. MYH7 gene Gene mutation Restrictive cardiomyopathy Hypertrophic cardiomyopathy Case report National Natural Science Foundation of China...

... of SAM, is an uncommon yet critical complication associated with haemodynamic collapse and syncope. This phenomenon warrants heightened attention during PIMSRA for the treatment of HOCM. Hypertrophic cardiomyopathy Percutaneous intramyocardial septal radiofrequency ablation Interventional procedure...

... through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. Abstract Background Mitral regurgitation (MR) is a frequent occurrence in hypertrophic cardiomyopathy (HCM), often explained by valvular or sub...

.../licenses/by/4.0/ ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background and Aims The feasibility and impact of high intensity exercise programmes in patients with hypertrophic cardiomyopathy (HCM) are unknown...

... and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. Abstract Hypertrophic cardiomyopathy (HCM) is a genetic condition primarily...

...-reuse-rights ) Abstract Background and Aims The European Society of Cardiology guidelines recommend a systematic search for diagnostic clues or ‘red flags’ (RFs) in patients with hypertrophic cardiomyopathy (HCM) to better tailor disease management. To date, the prevalence and clinical significance...

... 07 11 2024 27 12 2024 06 02 2025 Conflict of interest: None declared. Corresponding author. Tel: +43 (0)316 385 30173, Email: [email protected] Abstract Background Left ventricular outflow tract obstruction (LVOTO) is common in hypertrophic cardiomyopathy (HCM) but has...

.../ ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Aims In light of recent advances in imaging techniques, molecular understanding and therapeutic options in hypertrophic cardiomyopathy (HCM), we performed...

... was waived due to the anonymized nature of the data provided by the NHIS. Hypertrophic cardiomyopathy (HCM) is the most common inheritable heart disease, caused by pathogenic mutations in sarcomere genes. Its prevalence is higher than previously thought, estimated to be around 1 in 200 to 1 in 500...

... the original work is properly cited. Abstract Background Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular (LV) hypertrophy unexplained by increased afterload, often with concomitant outflow tract obstruction. Verapamil is commonly used to treat symptomatic...

... discussed, as it best mirrors the key concepts of the NYHA classification. ²¹ Abstract Introduction Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease. The impact of HCM on quality of life (QoL) and societal costs remains poorly understood. This prospective...

... adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope . Am J Cardiol   2002 ; 89 : 1405 – 1410 . 8 Mochizuki   T , Matsuo   Y , Sasaki   M , Morihisa   K , Tabata   S , Fukuda   T , et al...

... according to the following rule: none = 0, trace = 1, trace to mild = 1.5, mild = 2, mild to moderate = 2.5, moderate = 3, moderate to severe = 3.5, and severe = 4. ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; HCM, hypertrophic cardiomyopathy; ICD...

... [email protected]. Abstract Aims Myocardial disarray, an early feature of hypertrophic cardiomyopathy (HCM) and a substrate for ventricular arrhythmia, is poorly characterized in pre-hypertrophic sarcomeric variant carriers (SARC+LVH−). Using diffusion tensor cardiac magnetic resonance (DT-CMR) we...

...; Daniel L Jacoby; Stephen B Heitner; Stuart Kupfer; Fady I Malik; Lisa Meng; Amy Wohltman; James L Januzzi; on behalf of the SEQUOIA-HCM Investigators Natriuretic peptides Troponin Hypertrophic cardiomyopathy Aficamten Cytokinetics, Incorporated 10.13039/100014941 Adolph Hutter Professorship...

..., the severity of heart failure assessed using the NYHA functional classification, and the Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness of Breath (HCMSQ SoB) domain score. The HCMSQ SoB domain score ranges from 0 to 18 and assesses patient-reported shortness of breath in a 7-day recall period (see...

... comorbidities and/or who are exposed to potential treatment interactions. Hypertension is common in patients with hypertrophic cardiomyopathy (HCM), but its impact on the treatment of LVOTO is undefined. Case summary A 55-year-old man with severely obstructive symptomatic HCM and Grade I arterial...

... show ongoing elevation of T1times in the apex compared to the base, (E). Evolving ECG changes mimicking apical hypertrophic cardiomyopathy criteria, (F). Figure 3 Cardiac MRI at 15 months. Complete resolution of apical wall thickening, (A, C) diastole, (B...